RE: AACR posters22 Apr 2026 10:25
I'm not so sure its an either or in the way you describe D.
I don't think she is a charlatan, neither do i think she should be taken at face value.
She must, like all CEO's in her position, (plc, small company, needs financing to exist etc etc) potentially paint a lop sided position of the company's position.
I refer back to AS, not as alike for like comparison, but simply to remember how he stated the data and results and language used to keep confidence high and investors engaged. Most if not all here, at some time in his tenure, were very pleased with him and believed exactly what he said and took him at face value. It was only as it unravelled later that opinions changed.
I too think CC has framed AVCT to date so positively that it seems that she surely can't be leading us all up the garden path, but she may be caught to a degree in positive bias too? I am not saying she is but she said a deal would be in the not to distant future.
II believe now that statement was premature. But the words were carefully chosen. How long is "not to distant" in the future 2 weeks 2 months 2 years?
There was no context for investors to calibrate such a ambiguous statement.
There was never a clear communication to the time for enrolment on AVA6k, assumptions here were made it was all going full steam ahead but eventually we find that patients were still being selected many months later to at least my surprise.
I don't mind much of this. Its complicated and challenging and expensive to run these trials. But I do mind giving a false impression.
So I think its much more nuanced and her first objective is to keep the trial(s) going and the show on the road
Scepticism for me is always the order of the day. If this comes off she's brilliant, if it doesn't then, not so much but it will be in hindsight I think, before that judgement can be made.